Delving into the Latest Updates on Fentanyl Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Abstral Sublingual, E-Fen Buccal, Fentanyl citrate (JP17/USP)

+ [33]

Target

μ opioid receptor

Action

agonists

Mechanism

μ opioid receptor agonists(Mu opioid receptor agonists)

Therapeutic Areas

Nervous System DiseasesUrogenital DiseasesOther Diseases

Active Indication

Breakthrough PainCancer PainHyperemesis Gravidarum+ [1]

Inactive Indication

Anemia, Sickle CellBurnsChronic Pain+ [4]

Originator Organization

Rising Pharmaceuticals, Inc.

Active Organization

Istituto Gentili SrlTeva Pharmaceuticals Europe BV

Teikoku Seiyaku Co. Ltd.

+ [5]

Inactive Organization

Cephalon, Inc.

BioDelivery Sciences International, Inc.

Sentynl Therapeutics, Inc.

+ [5]

License Organization

Kunwha Pharmaceutical Co., Ltd.

Collegium Pharmaceutical, Inc.

Adalvo Ltd.

+ [5]

Drug Highest PhaseApproved

First Approval Date

United States (19 Feb 1968),

Anesthesia

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC28H36N2O8

InChIKeyIVLVTNPOHDFFCJ-UHFFFAOYSA-N

CAS Registry990-73-8

Injury and deformity of the upper extremity can result in dysfunction to nerves, tendons and bones which can lead to disability and pain.
Various techniques of regional anesthesia are frequently used for upper extremity surgery. Specifically, intravenous regional anesthesia, the Bier block, is an effective anesthetic technique. This technique, developed by Dr August Bier in 1908, provides complete anesthesia, a bloodless field, and eliminates the need for general anesthesia. However, it was not until the 1960s that this technique was reintroduced and used in upper extremity surgery due to several disadvantages and reports of major complications. Because of the dose of lidocaine and tourniquet time, there is potential for cardiac and neurological complications such as arrhythmias, seizures, and compartment syndrome the aim of this study To evaluate the effect of Systemic Fentanyl Infusion compared to addition of Fentanyl as An Adjuvant to Lidocaine in Bier Block for Controlling Pain in Patients Undergoing Hand Surgeries

Start Date01 Jul 2025

Sponsor / Collaborator

Assiut University

100 Clinical Results associated with Fentanyl Citrate

Login to view more data

100 Translational Medicine associated with Fentanyl Citrate

Login to view more data

100 Patents (Medical) associated with Fentanyl Citrate

Login to view more data

12,185

Literatures (Medical) associated with Fentanyl Citrate

01 Sep 2025·TALANTA

SERS detection of analgesics in serum based on Ag nanocubes for perioperative monitoring

Article

Author: Qin, Lei ; Ji, Yinghe ; Han, Lin ; Wu, Jing ; Wang, Yunpeng ; Zhu, Zhuo ; Li, Yang ; Sun, Tingting

Prompt and personalized perioperative analgesia management relies on sensitive and convenient monitoring of analgesics. We report a strategy for sensitive and reproducible SERS detection of analgesics based on Ag nanocubes, which have abundant intragranular hot spots on sharp corners and interparticle hot spots between gaps. Both theoretical simulations and R6G detection experiments indicated that the enhancement factor of Ag nanocube SERS platform reach to 10⁶ level. Quantitative and reproducible determination capabilities of this platform for six different analgesics with LOD as low as 500 pg mL^-1 were verified. Pharmacokinetic experiment of fentanyl in rat serum samples by SERS detection within 4 h presented consistent results with the UHPLC-MS/MS method. Valid examples of SERS detection for single or multiple analgesics in clinical patients' serums further proved the feasibility of this platform for perioperative analgesic monitoring.

01 Aug 2025·NEUROPHARMACOLOGY

A putative binding model of nitazene derivatives at the μ-opioid receptor

Article

Author: Shen, Jana ; Robertson, Michael J ; Skiniotis, Georgios ; Michaelides, Michael ; Stavitskaya, Lidiya ; Clayton, Joseph ; Shi, Lei

Nitazenes are a class of novel synthetic opioids with exceptionally high potency. Currently, an experimental structure of μOR-opioid receptor (μOR) in complex with a nitazene is lacking. Here we used a suite of computational tools, including consensus docking, conventional molecular dynamics (MD) and metadynamics simulations, to investigate the μOR binding modes of nitro-containing meto-, eto-, proto-, buto-, and isotonitazenes and nitro-less analogs, metodes-, etodes-, and protodesnitazenes. Docking generated three binding modes, whereby the nitro-substituted or unsubstituted benzimidazole group extends into SP1 (subpocket 1 between transmembrane helix or TM 2 and 3), SP2 (subpocket 2 between TM1, TM2, and TM7) or SP3 (subpocket 3 between TM5 and TM6). Simulations suggest that etonitazene and likely also other nitazenes favor the SP2-binding mode. Comparison to the experimental structures of μOR in complex with BU72, fentanyl, and mitragynine pseudoindoxyl (MP) allows us to propose a putative model for μOR-ligand recognition in which ligand can access hydrophobic SP1 or hydrophilic SP2, mediated by the conformational change of Gln124^2.60. Interestingly, in addition to water-mediated hydrogen bonds, the nitro group in nitazenes forms a π-hole interaction with the conserved Tyr75^1.39. Our computational analysis provides new insights into the mechanism of μOR-opioid recognition, paving the way for investigations of the structure-activity relationships of nitazenes.

01 Jul 2025·Forensic Chemistry

Analysis of substituted Cathinones and fentanyl analogs by gas chromatography-infrared spectroscopy (GC-IRD) using nitrogen carrier gas

Author: Warner, Marcus L.

Substituted cathinones and fentanyl analogs that are positional isomers can produce similar mass spectra and retention times, which poses challenges for their identification.A gas chromatog.-IR spectroscopy (GC-IRD) method, developed using nitrogen as the carrier gas, was employed as a complimentary technique to gas chromatog.-mass spectroscopy (GC-MS) for the accurate identification of positional isomers.Due to the global helium shortage and since Agilent helium (nitrogen switch) conservation modules were currently in use, nitrogen was selected and a novel method was developed for the anal. of controlled substances.A total method run time of 26 min for the anal. of 29 certified reference materials comprised of substituted cathinones and fentanyl analogs was achieved.A drug mixture was also analyzed to evaluate the resolution and retention time.Standards were prepared at concentrations of 100 μg/mL, 1 mg/mL and 2 mg/mL and analyzed over a 3-day period, where the 2 mg/mL concentrations of the standards were run in triplicate on day 1 and once on days 2 and 3.Twenty-seven of the standards were identified with a library match of 0.98 or higher for the 1 mg/mL concentrationEach standard experienced a retention time (RT) coefficient of variation (%CV) less than 3 %.For the drug mixture peak resolution exceeded 1.5 for each component.The GC-IRD validated method was found to be a suitable complementary anal. technique to GC-MS for analyzing substituted cathinones and fentanyl analogs, as demonstrated by the repeatable and reproducible RTs and library matches obtained during method validation.

37

News (Medical) associated with Fentanyl Citrate

21 May 2025

·www.einpresswire.com

Breaking News: A Courageous Milwaukee Woman, Shunda Garrett, Defied the Odds and Saved a Stranger's Life with Naloxone

After enduring the tragic loss of her brother and cousin to drug overdoses, Shunda saved a life with quick thinking Getting training is helpful, but it alone won’t save a life; having the naloxone nasal spray and knowing how to use it can save lives.” — Anita Garrett MILWAUKEE, WI, UNITED STATES, May 21, 2025 / EINPresswire.com / -- Her Mother, Anita Garrett, is a local leader in the 'You Have the Power to Save a Life Campaign,’ which is increasing access to naloxone in Milwaukee and other cities. A Milwaukee woman, who lost her brother and cousin to drug overdoses, alertly rescued a man on Tuesday, May 13, with life-saving naloxone. Shunda Garrett, 36, spotted a car driving erratically at 61st and North and swerving into a pole. The school security guard parked and ran over to the car, where the driver was losing consciousness. Immediately, she suspected the driver had suffered an overdose. She dashed back to her car. She grabbed naloxone, also known by the brand name Narcan, from the glove compartment and raced back to the vehicle. The female passenger in the car fled the scene. With the help of bystanders, they pulled the unconscious driver from the vehicle, and Garrett administered the naloxone nose spray that revived the driver. A short time later, police arrived at the scene. “This is the exact message we are trying to convey,” asserted her mother, Anita Garrett. She is actively engaged in the “You Have the Power to Save Lives” campaign, which aims to increase access to naloxone in Black communities, and she relayed the details of the rescue. “I am so proud of Shunda. Everyone must realize that they need to have naloxone on them to save a life.” Anita Garrett maintained that the campaign seems to be working. “Shunda had training on how to use naloxone at her school, but this campaign has emphasized the importance of having naloxone with you,” she said. “That’s what she realized, and that’s the message we must also convey to the community. Getting training is helpful, but it alone won’t save a life; having the naloxone nasal spray and knowing how to use it can save lives.” Back in 2011, when Shunda was 22, her brother Sammie Garrett, 31, overdosed on ecstasy pills laced with fentanyl when he was partying with friends. The Food and Drug Administration had approved naloxone in 1971, but it wasn’t widely available when Sammie needed it. As the overdose unfolded, his friends were slow to call the authorities because they didn’t want to get arrested. “The urgency of the situation would have been clear to me, but it wasn’t to those around him,” said Anita Garrett. “Sammie might still be with us today if his friends had reacted quicker.” A few years later, Romeo Thames, 35, who was Shunda’s cousin and Anita’s nephew, also fell victim to an overdose. Naloxone was there this time; someone had it in the car they drove in, but they didn’t know how to use it. Calling it a tragic loss, Anita Garrett said he died because the Black community hadn’t fully embraced naloxone as a lifesaver. “Two people very close to me are gone because our community doesn’t know what to do when someone overdoses,” she said. “There is a fear and a stigma around nearly everything regarding drugs. I can’t stop people from using drugs, but I can educate my community about how to save lives with naloxone.” Today, Anita Garrett is committed to the You Have the Power to Save Lives campaign and shares her personal story in videos ( https://www.instagram.com/reel/DHqk80YuDw8 ) and interviews https://content.communityjournal.net/content/uploads/20250403101805/MCJ040225-PAGES.pdf ). In addition to Milwaukee, the campaign is in Philadelphia, PA; Louisville, KY; Newark, NJ; Durham, NC; Albuquerque, NM; and Detroit, MI, locations where a disproportionate number of overdose deaths still plague Black communities. A website, YouCanSaveLives.org, highlights the life-saving potential of naloxone and provides guidance on its use. The website also directs visitors to locations in Milwaukee and other target cities, where free naloxone is available, making it a valuable resource for those seeking to learn more about naloxone and its potential to save lives. The Centers for Disease Control and Prevention (CDC) recently reported that overdose deaths fell by nearly 30,000 last year, down 27%. But while the overdose rate has edged downward, it remains a crisis in many Black communities. The campaign, in a Data Brief, noted that: • Despite an overall decline in overdose deaths in Milwaukee County in 2024, the overdose death rate for Black Milwaukee residents remained twice as high as the rate for whites in the city. • In 2024, Black Milwaukee residents accounted for 42% of all overdose deaths in the county , despite accounting for 27% of the county’s population. • Overdose deaths in the City of Milwaukee are concentrated in the predominantly Black neighborhoods of the Northside. “My commitment to saving lives in our community is deeply personal,” said Anita Garrett. “I'm a recovering substance user myself, and I'm driven by the desire to prevent another mother from experiencing the pain and suffering that I have endured. “ ### About Vital Strategies: Vital Strategies is a global health organization that believes every person should be protected by a strong public health system. Our overdose prevention program works to strengthen and scale evidence-based, data-driven policies and interventions to create equitable and sustainable reductions in overdose deaths in several U.S. states and local jurisdictions. About the National Black Harm Reduction Network: The National Black Harm Reduction Network is dedicated to advancing harm reduction principles that optimize health and wellness for Black people who are disproportionately harmed by public health initiatives, the criminal legal system, and drug policies. Tony Newman Vital Strategies email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

07 Apr 2025

·www.prnewswire.com

Elysium Therapeutics Announces Development of Overdose Rescue Technology Specifically Designed for Oral Fentanyl

Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) targets an unmet challenge in the illicit opioid crisis as current rescue medications are not designed for synthetic opioids, including oral fentanyl. LYONS, Colo., April 7, 2025 /PRNewswire/ -- Elysium Therapeutics, an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral opioids, including synthetic opioids like fentanyl, announced its plan to accelerate development of its Synthetic Opioid Overdose Prevention and Reversal (SOOPR™) technology. The company has completed in vivo proof-of-concept studies and expects to file an Investigational New Drug (IND) application in 2026. SOOPR is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone prodrug formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 to 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. "Fentanyl overdoses often require very high, or repeated, doses of short-acting opioid antagonists to effect a successful rescue," said Greg Sturmer, Co-Founder and CEO of Elysium Therapeutics. "Unfortunately, many who overdose face a rapid recurrence of symptoms, known as re-narcotization, which can lead to respiratory depression and increase the likelihood of hypoxic brain injury or death. SOOPR is designed to address this situation, and Elysium is now focused on advancing its development as a potential first-ever, faster-onset, longer-acting opioid rescue therapy specifically intended to treat fentanyl overdose." Currently approved short-acting opioid antagonists like Narcan and Opvee® were designed to effectively counteract overdoses from opioids such as heroin and oxycodone. However, these rescue agents are frequently ineffective in the management of synthetic opioid overdoses1, with 20 to 45% of overdose victims initially rescued with naloxone experiencing a re-narcotization event. According to reports from multiple state-affiliated health agencies, 31 to 39% of fentanyl overdose decedents had been administered naloxone.2 Data from in vivo proof-of-concept studies of SOOPR demonstrated a more rapid onset of action versus naloxone (Narcan) and a significantly longer duration of action. This profile is especially useful in counteracting oral fentanyl overdoses associated with prolonged fentanyl absorption and exposure that often outlast the short-acting profile of Narcan. "In designing SOOPR, Elysium recognized that synthetic opioids – now the number one killer of adults aged 18 to 45 in the U.S. – are particularly lethal," said Tom Jenkins, Ph.D., Co-Founder and Chief Scientific Officer of Elysium Therapeutics. "Patients initially treated with a rapid-acting, long-duration reversal agent, such as SOOPR, are expected to have less risk of hypoxic brain injury, cardiovascular events, re-narcotization, and death. Further, rescue interventions with SOOPR are expected to require less intensive monitoring in both the ambulance and emergency department and increase the likelihood of survival. Additionally, SOOPR is designed to be delivered by intramuscular injection, either using a pre-filled syringe or autoinjector, which has been demonstrated to be more rapid and predictable than intranasal delivery in urgent settings, where every second counts." "In addition to preventing overdose deaths from recreational, illicit use, the Department of Defense (DOD) has made clear the importance of improving opioid overdose rescue as a needed medical countermeasure," added Sturmer. "The DOD reported that the availability of synthetic opioids, such as fentanyl and its derivatives, represents a significant threat as a chemical weapon, which could be easily disseminated as a weapon of mass destruction into air, water or food supplies, putting countless lives at risk. We look forward to working with defense and government organizations as we develop SOOPR as a tool to prevent injury and death in these worrisome scenarios." About SOOPR™ (Synthetic Opioid Overdose Prevention and Rescue) SOOPR (Synthetic Opioid Overdose Prevention and Reversal) is a rapid-onset, long-acting rescue agent specifically designed to address overdose from synthetic opioids, including oral fentanyl. SOOPR utilizes a proprietary long-acting naloxone reversal formulation with faster onset kinetics versus Narcan® delivered via long-acting injection (LAI) technology. The technology is designed to rapidly restore respiration and provide 18 – 24 hours of effective opioid blockade to minimize the risk of re-narcotization, while also providing protection from same-day re-use of opioids. SOOPR has been endorsed by first responders and OUD treatment professionals as the effective solution urgently needed to address the global opioid overdose epidemic. About Elysium Therapeutics Elysium is an emerging biopharmaceutical company developing treatments specifically designed to rescue and reverse overdoses caused by oral synthetic opioids, including fentanyl. Elysium is working to establish new standards of safety in the opioid industry by developing SMART™ (Safer Medicines Alleviate Risks and Trauma) products, first- and best-in-class medicines that address the limitations and dangers associated with opioids and overdose rescue agents to reduce suffering from opioid-use disorder, opioid overdose, and acute pain. Elysium's lead technology, SOOPR™ (Synthetic Opioid Overdose Prevention and Reversal), is a long-acting opioid antagonist specifically designed to address oral synthetic opioid, including fentanyl, overdose. Tens of thousands of unnecessary overdose deaths each year exemplifies the critical shortcomings of currently available rescue agents, including naloxone and nalmefene. In addition, Elysium is developing oral-overdose protected (O2P™) hydrocodone for the treatment of moderate-to-severe acute pain. For more information, please visit . 1 Rachael Rzasa Lynn and JL Galinkin Ther Adv Drug Saf 2018, Vol. 9(1) 63–88 (Also see footnotes 8, 9, and 10 for additional discussion). 2 Watson, W.A., Steele, M.T., Muelleman, R.L., Rush, M.D., 1998. Opioid toxicity recurrence after an initial response to naloxone. J. Toxicol. Clin. Toxicol. 36 (1-2), 11–17. . SOURCE Elysium Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Drug Approval

24 Mar 2025

·www.biospace.com

Tempero Raises $70M to Fight Substance Use Disorders

iStock, Anatolii Frolov The company, launched with help from ex-Novartis executives, is targeting glutamate signaling in the brain to help treat alcohol- and cocaine-use disorders, among other indications. Tempero Bio, a Bay Area–based biotech, has raised $70 million in Series B financing to develop therapies for substance use disorders. The financing round, announced Monday, will push the company’s lead molecule TMP-301 through two Phase II clinical trials for alcohol- and cocaine-use disorders, on top of “Phase III-enabling activities” for other indications and formulations. “Substance use disorders affect 48 million Americans and contribute to more than 100,000 deaths per year.  We urgently need more effective treatments to help patients and families with these diseases,” Tempero CEO and President Ricardo Dolmetsch said in a company statement. “TMP-301 is a novel therapy that helps prevent relapse by targeting the underlying biology of addiction.” Tempero was birthed from a 2020 partnership between Aditum Bio (Tempero’s continuing benefactor) and Soshei Heptares (now known as Nxera). Aditum is an investment firm run by Joe Jimenez, former CEO of Novartis, and Mark Fishman, former head of the pharma’s R&D hub, known as Novartis Biomedical Research. Aditum funded Tempero, while Soshei licensed a suite of metabotropic glutamate receptor 5 (mGlu5) NAM modulator molecules, including TMP-301. These molecules modulate glutamate signaling in the brain, a pathway with potential applications in treating substance use disorders like alcohol abuse and smoking, as well as depression and certain neurodegenerative disorders . Tempero got investigational new drug (IND) clearance for TMP-301 in early 2023, as well as a $5.3 million grant from the National Institutes of Health to study it in cocaine use disorders. Tempero’s latest financing round, led by 8VC with additional money from Aditum Bio, Khosla Ventures and other undisclosed participants, is another sign of biopharma’s interest in developing medical treatments for substance use disorders. A variety of companies are attempting to directly neutralize a drug, like fentanyl, and its effect on the body, while others are looking to use GLP-1 drugs to reduce cravings. Altimmune, Novo Nordisk and Eli Lilly are all currently conducting or preparing for clinical trials targeting alcohol-use disorders using GLP-1s.

Phase 2Phase 3

100 Deals associated with Fentanyl Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01399	Fentanyl Citrate	N02AB03 N01AH01	DB00813

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pain	United States	Adalvo Ltd.	16 Jul 2009
Breakthrough Pain	European Union	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Iceland	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Liechtenstein	Teva Pharmaceuticals Europe BV	04 Apr 2008
Breakthrough Pain	Norway	Teva Pharmaceuticals Europe BV	04 Apr 2008
Cancer Pain	United States	Cephalon, Inc.	04 Nov 1998
Hyperemesis Gravidarum	China	Yichang Humanwell Pharmaceuticals Co., Ltd.	01 Jan 1981
Anesthesia	United States	Rising Pharmaceuticals, Inc.	19 Feb 1968

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Head and Neck Neoplasms	Phase 3	Italy	L. Molteni & C. dei F.lli Alitti Società di Esercizio SpA	01 Sep 2014
Chronic Pain	Phase 3	United States	Cephalon, Inc.	01 Dec 2006
Low Back Pain	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neuralgia	Phase 3	United States	Cephalon, Inc.	01 Sep 2005
Neoplasms	Phase 3	United States	Cephalon, Inc.	01 Apr 2004
Anemia, Sickle Cell	Phase 2	United States	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Canada	Cephalon, Inc.	01 Oct 2006
Anemia, Sickle Cell	Phase 2	Puerto Rico	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	United States	Cephalon, Inc.	01 Oct 2006
Burns	Phase 2	Canada	Cephalon, Inc.	01 Oct 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04230681 (CTgov)	Early Phase 1	Sleep Apnea, Obstructive \| Tonsillitis	189	Hydromorphone (Hydromorphone)	aocsaswcya = tmzipxtrfp ofkvsfoowe (avhaufccfv, porgejnkxy - ptsbxcdavd) View more	-	18 Dec 2024
				Fentanyl (Fentanyl)	aocsaswcya = xgqqbxiphh ofkvsfoowe (avhaufccfv, mruzkrwoey - dbswuvixpb) View more
NCT03435003 (CTgov)	Phase 4	Postoperative Nausea and Vomiting \| Vomiting	83	dexmedetomidine+Compazine+Total intravenous anesthesia+Fentanyl+scopolamine transdermal+sugammadex+Reglan+Propofol+Ondansetron+Aprepitant 80 mg Oral Capsule+Dexamethasone (Intervention Arm)	qtmttvlrwx = ubzxkpucdf zqowbfmapq (jpffyiroju, gkeyjmuymb - acumnigjra) View more	-	14 Feb 2024
				Compazine+sugammadex+Reglan+Sevoflurane+Desflurane+Ondansetron+Dexamethasone (Control Arm)	qtmttvlrwx = brgvhnmhhc zqowbfmapq (jpffyiroju, ufpmgxavka - hntpihbunk) View more
NCT03115151 (CTgov)	Phase 4	Pain	46	Fentanyl+Bupivacaine (Patient-Controlled Epidural Analgesia)	zetdgpvhec(peochpadpt) = pwfgrhebsd cghnyhwnom (tpjphpraeb, 24.69) View more	-	26 Oct 2023
				Hydromorphone (Intravenous Patient-controlled Analgesia)	zetdgpvhec(peochpadpt) = dzkwlfarof cghnyhwnom (tpjphpraeb, 25.41) View more
NCT01362998 (CTgov)	Not Applicable	Analgesia	2	morphine (Preservative Free Morphine)	hnhrkgqglf(zzgwttvene) = hhlpzmxhem pzfuonnsjg (wpckcegvti, khkhufqqje - poruluxexh) View more	-	14 Nov 2022
				Fentanyl (Fentanyl Infusion)	lqetsajajx = leqnsnhxqn ftoxxdwwvj (hoyvyqrjjy, tieicpohhp - ensjohwuqi) View more
NCT03938857 (DOSE, CTgov)	Phase 1	Critical Illness \| Mechanical ventilation complication	30	Fentanyl (Fen. SOC+Saline Placebo (Bolus+Infusion))	lvclzkfkwe(jfkhqgyhbo) = nitutjmbsr lcpqziyydp (xureclrvdi, 2.15) View more	-	05 Nov 2021
				dexmedetomidine+Fentanyl (Fen. SOC+Dex.(.5mcg/kg + .25mcg/kg/hr))	lvclzkfkwe(jfkhqgyhbo) = hmehhednin lcpqziyydp (xureclrvdi, 1.53) View more
NCT02747875 (CV_RCT_M_F, CTgov)	Not Applicable	Pain, Postoperative	26	Fentanyl (Control - Fentanyl)	bsjbjtllja(icvwqtedyr) = huaaciiewb zsavclyoqy (ysfkvfpfri, 0.21) View more	-	01 Jun 2021
				Methadone (Treatment - Methadone)	bsjbjtllja(icvwqtedyr) = chttsqhqwu zsavclyoqy (ysfkvfpfri, 0.24) View more
NCT02056288 (CTgov)	Phase 4	Fractures, Bone \| Pain, Postoperative	78	Ropivacaine (Ultrasound Guided Supraclavicular Block)	sfcsvvyxgx(kdklkxienh) = rkcenbwysf kxbxlgzelr (qowxsnlpmm, ffgfoqhsce - qkptcmaqaa) View more	-	21 May 2021
				Fentanyl (IV Opioids)	sfcsvvyxgx(kdklkxienh) = vdzonznurd kxbxlgzelr (qowxsnlpmm, vaderrlvoh - qaezglanak) View more
NCT02480114 (CTgov)	Phase 3	Mucositis \| Radiodermatitis \| Head and Neck Neoplasms	79	Hydrocodone/Acetaminophen+Pain Therapy+Fentanyl+Ibuprofen+Oxycodone/Acetaminophen (Arm I Standard of Care)	ossajqofdu(jxfyqgzinz) = akaeykxgop sqsbfgyjto (gqumdxdggr, mbdeesijen - wxaackzzmv) View more	-	24 Sep 2020
				Hydrocodone/Acetaminophen+Pain Therapy+Fentanyl+Ibuprofen+Gabapentin+Oxycodone/Acetaminophen (Arm II Standard of Care Plus Gabapentin)	ossajqofdu(jxfyqgzinz) = sifyzkgnia sqsbfgyjto (gqumdxdggr, czdcsfpllh - uvgzvnbats) View more
NCT02798835 (CTgov)	Phase 4	Pain	180	Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Bupivacaine (Adductor Canal Block)	awlarsmlep(oaksjobskc) = ndbwcoewmm hmpmmafdzi (dzygrkloam, fdjxuykaoh - nbgibbzigs) View more	-	04 Sep 2020
				Adductor canal block+Ropivacaine 0.5% Injectable Solution+Fentanyl+Dexamethasone+Bupivacaine+dexamethasone (Adductor Canal Block With Dexamethasone)	awlarsmlep(oaksjobskc) = qtdnuktids hmpmmafdzi (dzygrkloam, ixwhbvkvle - dysjyxpdwz) View more